Khiron Life Sciences Corp Stock (TSXV: KHRN) (OTCQB: KHRNF) - Investor Dashboard


Khiron Life Sciences
TSXV Ticker: KHRN
OTCQB Ticker: KHRNF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 35
Established: 2017
CEO: Alvaro Torres

Summary

Fiscal Year-End: December
Facilities: 1
Dried Flower:  Production
Extracts: Production
Number of Patients: N/A
Headquarters: Toronto, ON

Financials (02/28/18)

Cash on hand: $13.8mm
Fixed Investment: $0.2mm
Shareholders’ Equity: $13.3mm
Revenues – Last Quarter: na
Adj. Gross Margin : na
EPS : na

Capital Structure (05/30/18)

Last Financing: 11.23mm Units at $1.00
Basic Shares: 46.9mm
Warrants: 16.3mm
Options: 3.0mm
Diluted Shares: 66.2mm

Company Brief

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) is a Canadian integrated medical cannabis company headquartered in Toronto, Ontario with its operating subsidiary and core operations in Colombia. Khiron holds a first-mover advantage with one of the first licenses granted for legal commercial cultivation and production of medical cannabis in Colombia and the first company to implement U.S. DEA standard pharmaceutical compliance protocols in security and safety.

Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Khiron’s mission is to drive medical cannabis innovation and bring world-class best practices to Colombia and Latin America

Columbian Medical Cannabis Operations
Site Tour by MidasLetter Films


Highlights

  • First company to implement U.S. DEA standard pharmaceutical compliance protocols in security and safety.
  • High-THC and Low-THC Cultivation and Production Licenses.
  • Executed Israeli MOU for medical grade strain genetics.
  • Initiated medical trials with Colombian Neurological Association.
  • Attractive capital structure with 31.0% insider pro forma ownership.

Growth Strategy

  • Leased 4.5 hectares of land in prime agricultural region of Colombia. Optioned an adjacent 15.5 hectares for further expansion.
  • Future product pipeline includes branded pharmaceutical products.

  • Latin American Expansion potential opportunities in Peru, Chile, Mexico, Brazil and Argentina.

Differentiators

  • One of the first licenses granted for legal commercial cultivation and production of medical cannabis in Colombia.
  • First Colombian company to complete the Canadian listing process.
  • Fertile agricultural region in Colombia, an ideal jurisdiction for cultivation.
  • Targeted therapeutics strategy with the build out of Khiron cannabis clinics.

Curated Stories & News


Visit Khiron Life Sciences Corp.
at www.khiron.ca.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Khiron Life Sciences Corp. is a client of NCV Media, LLC. Read our full disclaimer.